Intranasal esketamine use in bipolar disorder: A case report
Mental Health Clinician July 1, 2021 Courtney Skriptshak, Ashley Reich 11 citations
Abstract Over the past few years, intranasal esketamine has been FDA-approved for treatment-resistant depression as well as MDD with suicidal ideation. In the clinical trials leading to the recent FDA approvals, subjects with a diagnosis of bipolar disorder were excluded from participation in the trial. The manufacturer of intranasal esketamine states that it “has not been studied, and is not...